235 East 42nd Street
About Pfizer Inc.
Imagine touching the lives of people everywhere. Imagine reaching beyond the ordinary and impacting something greater than the bottom line. Imagine influencing some of the most critical issues facing healthcare today.
At Pfizer Global Research & Development (PGRD), Pfizer’s visionary discovery and development division and the largest research-based biomedical and pharmaceutical company in the world, we're not content waiting to witness the evolution of our industry. Instead, we’re driven by science, building on our current successes and capabilities, playing a critical role in developing the most compelling story of scientific discoveries.
To date, PGRD has brought to market a wide range of medicines, such as Lipitor® (atorvastatin calcium), Zithromax® (azithromycin), Viracept® (nelfinavir mesylate), Zoloft® (sertraline hydrochloride), Viagra® (sildenafil citrate), and our newest smoking cessation medicine, Chantix® (varenicline). And, today, with a broad research pipeline that spans many therapeutic areas, we are determined to bring even more cures to the marketplace.
But there is much more work to be done and we can’t do it alone. We’re always seeking those who share our belief that science can improve our world, that by working together we can bring exciting new therapies to patients on a global scale and forever change the way we improve the health and well-being of all people.
Why Join Pfizer?
Pfizer offers the opportunity to work on promising research, access to unparalleled resources and world-class facilities, and the chance to work with some of the brightest and most driven individuals in the pharmaceutical industry.
At Pfizer, we build our success on the innovation, skills, and entrepreneurial spirit of each of our colleagues. As an integral member of our team, you'll find myriad opportunities to assert your professional independence as you generate results that will advance our ultimate goal of creating life-enhancing therapies.
In addition to creating the environment for innovation, our values have led to numerous corporate awards acknowledging excellence in many domains - with investors, our business partners, and our employees. We've been praised as “One of the 100 Best Companies for Working Mothers” by Working Mother® Magazine (9/07), honored with “The Best Employers for Healthy Lifestyles 2007 Award” by the National Business Group on Health (5/07), and awarded by the Women's Business Enterprise National Council on its annual listing of America's Top Corporations for Women's Business Enterprises (3/07).
At PGRD, your success is critical to our success. PGRD offers world-class career opportunities, directing resources and time that result in a high-level scientific professional track. Our employees and external rankings with the leading authorities attest to the fact that PGRD is one of the best companies to work for - where you choose a lifestyle - not just a job.
• La Jolla, CA
Located north of downtown San Diego, La Jolla boasts southern California's most beautiful and majestic coastline, with an abundance of cultural, outdoor recreation, and big city activities. Home to Salk Institute and Scripps Research Institute - two renowned academic institutions - and many major biotechnology and telecommunications firms, La Jolla offers a rich environment for both scientists and engineers.
• New London and Groton, CT
Located on the southeastern Connecticut seashore in a historical New England vacation area known for its seafood, easy pace of living, and nautically related recreational activities. It's also within reasonable driving distance to a wealth of greater academic institutions, and within a couple of hours of Boston and New York.
• St. Louis, MO
Known as the Gateway to the West, St. Louis is a diverse, vibrant metropolitan area of 2.5 million, with a broad-based economy. Residents enjoy professional sports teams, a world-class symphony orchestra, botanical gardens, and numerous other outdoor activities. Additionally, scientists have the opportunity to collaborate with researchers at Washington University School of Medicine.
• Sandwich, UK
Sandwich, once a major port in England but now 2 miles from the sea, is one of the best-preserved Medieval towns in the UK, with its old town walls and "Kent Peg" roof houses. Situated close to the city of Canterbury and only 80 miles from London, the area is steeped in history and is ideal for those who enjoy water sports. The rail links across the English Channel also mean that you can be in France within an hour, providing access to the whole of Europe.
At PGRD, we celebrate the talents and diversity of our employees. We respect our employees' lives and provide a multitude of resources and supports to help foster a work/life balance. Also, in addition to our outstanding career opportunities and quality of life, we offer a wide array of topnotch and leading-edge benefits, competitive compensation, and exceptional long-term financial rewards designed to ensure your well-being and financial security. We offer you choices so you can craft a plan that meets your individual and family needs.
Your talent can change the world. Join us.
To learn more about our people, our products, and our plans for the future, visit www.pfizer.jobs
We’re proud to be an equal opportunity employer and welcome applications from people with different experiences, backgrounds, and ethnic origins.
Founder: Charles Pfizer
CEO: Ian C. Read
CMO: Freda C. Lewis-Hall, M.D., DFAPA
CFO: Frank D’Amelio
Please click here for clinical trial information.
For more information, visit
www.pfizer.com and follow us on www.twitter.com/Pfizer.
Tweets by Pfizer
Innovating for Healthier Lives
3550 articles with Pfizer Inc.
Despite the recent dismal news regarding Alzheimer’s drug development, the U.S. Food and Drug Administration (FDA) recently proposed new guidelines for developing drugs for the disease.
Detailed results from the JAVELIN Lung 200 trial will be submitted for presentation at an upcoming medical congress.
The Phase 3 program is the first trial in the JAK1 Atopic Dermatitis Efficacy and Safety global development program.
BC Platforms today announces that Pfizer Finland will be using its technology solutions and research platform, including BCRQUEST.COM, to study data in cardiovascular diseases.
U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib
Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the company’s New Drug Application for lorlatinib.
Improving data tracking and analysis via integrated data collection and enhanced data association can potentially help streamline data-focused development.
Under the terms of the agreement, DL Medicine will screen and collaborate with Pfizer in producing new chemical entities against pre-selected targets from multiple therapeutic areas.
Late-stage data shows the use of Pfizer's prostate cancer drug Xtandi plus ADT significantly reduced the risk of developing metastases or death by 71 percent.
Full-year 2017 revenues totaled $52.5 billion, a decrease of $278 million, or 1%, reflecting a slight operational decline of $20 million, or less than 1%, and the unfavorable impact of foreign exchange of $259 million, or less than 1%.
During its financial report this morning, Pfizer released an update of its pipeline which includes the discontinued projects.
This is a market like the world has never seen.
The trial demonstrated equivalence in overall response rate for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma.
1/23/2018The year is already off to a good start with mergers and acquisitions in the biopharma industry.
The companies will collaborate on research to study a previously unrecognized role for peripheral immune cells in the pathology of central nervous system disorders.
Life sciences professionals don't have to look far for opportunity in Genetown.
Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma
Kite announced it has entered into a clinical trial collaboration with Pfizer Inc. to evaluate the safety and efficacy of the investigational combination of Yescarta (axicabtagene ciloleucel) and Pfizer's utomilumab, a fully humanized 4-1BB agonist monoclonal antibody, in patients with refractory large B-cell lymphoma.
1/17/2018We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals.
Circle Pharma Announces Publication in Journal of Medicinal Chemistry of Results from Collaboration with Pfizer Inc.
The goal of the collaboration was to deploy Circle’s rational design platform for macrocycle therapeutics in order to improve the drug-like characteristics of an existing macrocycle compound, and in particular to develop a cell permeable, orally bioavailable compound with enhanced target affinity.
The partnership focuses on development, regulatory support and commercialization of companion diagnostics.
The company, which now has 11 personnel, is a CRO focused on infectious disease research.